<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975256</url>
  </required_header>
  <id_info>
    <org_study_id>849-014</org_study_id>
    <nct_id>NCT04975256</nct_id>
  </id_info>
  <brief_title>Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)</brief_title>
  <official_title>A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety, tolerability, drug levels, molecular effects and clinical&#xD;
      activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced&#xD;
      solid tumors that have a KRAS G12C mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate safety, tolerability, pharmacokinetics, metabolites,&#xD;
      pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963&#xD;
      in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally&#xD;
      available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation</measure>
    <time_frame>20 months</time_frame>
    <description>Number of participants with treatment related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Pharmacokinetics of the combination regimen</measure>
    <time_frame>20 months</time_frame>
    <description>Blood plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish Maximum Tolerated Dose</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with dose limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary clinical activity of the combination regimen</measure>
    <time_frame>20 months</time_frame>
    <description>Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Malignant Neoplasm of Colon</condition>
  <condition>Malignant Neoplasm of Lung</condition>
  <condition>Malignant Neoplastic Disease</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRTX849</intervention_name>
    <description>KRAS G12C inhibitor</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
    <other_name>KRAS G12C inhibitor</other_name>
    <other_name>adagrasib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1701963</intervention_name>
    <description>SOS1 Inhibitor</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
    <other_name>SOS1 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation&#xD;
             (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)&#xD;
&#xD;
          -  Unresectable or metastatic disease&#xD;
&#xD;
          -  No available treatment with curative intent&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intestinal disease, inflammatory bowel disease, major gastric surgery, or&#xD;
             other gastrointestinal conditions likely to alter absorption of study treatment or&#xD;
             result in inability to swallow&#xD;
&#xD;
          -  Other active cancer&#xD;
&#xD;
          -  Cardiac abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>1-844-893-5530</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald L Shazer, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Next Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS G12C</keyword>
  <keyword>SOS1 Inhibitor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>CRC</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>adagrasib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adagrasib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

